---

---

entities : Teva pharmaceutical industries ltd   

save search

---

Global Epinephrine Markets, 2017-2022, 2022-2027F, 2032F: Product Innovation Drives Growth, Rising Prevalence of Chronic Respiratory Diseases Driving Demand
Published: 2023-11-14 (Crawled : 15:30) - prnewswire.com
VTRS | $11.11 0.09% 0.09% 3.5M |

Health Technology

| 24.25% | O: 1.68% H: 2.09% C: 1.32%
BHC | $8.6 -0.69% 0.0% 2.1M |

Health Technology

| 33.84% | O: 3.37% H: 2.07% C: 0.59%
ABT | News | $105.27 -0.6% -0.15% 7.3M |

Health Technology

| 11.4% | O: 0.94% H: 0.0% C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| 0.29% | O: 0.68% H: 0.0% C: 0.0%
respiratory innovation global epinephrine

---

Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)
Published: 2023-11-14 (Crawled : 12:00) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K |

n/a

| 41.13% | O: 0.33% H: 3.87% C: -0.55%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -1.68% | O: 0.17% H: 0.0% C: 0.0%
KMDA | $5.075 -0.1% -0.1% 6.5K |

Health Technology

| 6.37% | O: 0.21% H: 1.67% C: 1.25%
avt04 stelara pharma biosimilar authorization

---

Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
Published: 2023-11-13 (Crawled : 13:30) - biospace.com/
TEVA | $12.78 -3.03% -0.24% 9M |

Health Technology

| 51.84% | O: -0.92% H: 4.53% C: 2.56%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -2.17% | O: -0.5% H: 0.0% C: 0.0%
RPRX | $27.885 1.0% 0.99% 2.1M |

Health Technology

| 1.43% | O: -0.44% H: 0.59% C: 0.04%
pharma royalty teva program

---

Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
Published: 2023-11-13 (Crawled : 13:00) - globenewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -2.17% | O: -0.5% H: 0.0% C: 0.0%
RPRX | $27.885 1.0% 0.99% 2.1M |

Health Technology

| 1.43% | O: -0.44% H: 0.59% C: 0.04%
pharma royalty teva program

---

Challenges in Transparency and Control Hamper Merchant API Market Growth Despite Pharmaceutical Industry Expansion
Published: 2023-11-10 (Crawled : 00:20) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| Email alert Add to watchlist
LZAGY | $57.3 0.02% 33K |

Professional, Scientific, and T...

| Email alert Add to watchlist
SNYNF | News | $92.7 -2.18% 1.4K |

Health Technology

| Email alert Add to watchlist
TEVJF | $12.37 -24.22% 380 |

Health Technology

| Email alert Add to watchlist
LZAGF | $579.0 -19.1% 49 |

Health Technology

| Email alert Add to watchlist
TMO | News | $541.52 -1.05% 0.61% 2.1M |

Health Technology

| Email alert Add to watchlist
control expansion growth market

---

STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
Published: 2023-11-10 (Crawled : 14:30) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K |

n/a

| 46.49% | O: 0.12% H: 7.18% C: 3.56%
KMDA | $5.075 -0.1% -0.1% 6.5K |

Health Technology

| 9.57% | O: -0.22% H: 0.86% C: 0.86%
biosimilar chmp positive stelara

---

Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
Published: 2023-11-08 (Crawled : 14:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K |

Health Technology

| 1.88% | O: -0.33% H: 0.0% C: 0.0%
TEVA | $12.78 -3.03% -0.24% 9M |

Health Technology

| 45.8% | O: 2.54% H: 3.23% C: -1.29%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| 0.98% | O: 1.62% H: 0.0% C: 0.0%
revenue teva financial results

---

Alvotech to Present at the Jefferies 2023 London Healthcare Conference
Published: 2023-11-07 (Crawled : 13:00) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K |

n/a

| 47.85% | O: -0.12% H: 2.33% C: 0.47%
KMDA | $5.075 -0.1% -0.1% 6.5K |

Health Technology

| 7.04% | O: -0.42% H: 0.42% C: 0.21%
conference

---

Clonidine Micropellet Epidural Injections Fuel Growth in Global Sciatica Treatment Market
Published: 2023-11-01 (Crawled : 23:00) - prnewswire.com
VTRS | $11.11 0.09% 0.09% 3.5M |

Health Technology

| 24.66% | O: 0.67% H: 0.22% C: -0.56%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -1.25% | O: -1.09% H: 1.03% C: 0.91%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -2.7% | O: -0.89% H: 0.0% C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -0.28% | O: 3.0% H: 0.0% C: 0.0%
treatment global growth market

---

Muscle Wasting Disorders Market Predicted to Reach USD 45.4 Billion by 2031, Garnering 15.1% CAGR: TMR Report
Published: 2023-10-30 (Crawled : 15:30) - prnewswire.com
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| 0.88% | O: 1.69% H: 0.25% C: -0.07%
SRPT | $116.59 -1.1% -1.12% 500K |

Health Technology

| 10.35% | O: 1.05% H: 1.86% C: -0.28%
PTCT | $24.71 -1.79% -1.82% 820K |

Health Technology

| 35.93% | O: 0.38% H: 5.49% C: 0.86%
IONS | $40.81 -0.24% -0.25% 990K |

Health Technology

| -7.36% | O: -0.16% H: 1.58% C: 0.05%
report reach disorders market

---

Data Logger Market is Anticipated to Reach US$ 12 billion by 2031 Says, Transparency Market Research
Published: 2023-10-30 (Crawled : 14:30) - prnewswire.com
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| 0.88% | O: 1.69% H: 0.25% C: -0.07%
SRPT | $116.59 -1.1% -1.12% 500K |

Health Technology

| 10.35% | O: 1.05% H: 1.86% C: -0.28%
PTCT | $24.71 -1.79% -1.82% 820K |

Health Technology

| 35.93% | O: 0.38% H: 5.49% C: 0.86%
IONS | $40.81 -0.24% -0.25% 990K |

Health Technology

| -7.36% | O: -0.16% H: 1.58% C: 0.05%
reach research market

---

Increasing Prevalence of Laryngeal Cancer Fuels Growth in Laryngeal Cancer Therapeutics Market
Published: 2023-10-27 (Crawled : 02:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K |

Health Technology

| -11.93% | O: -18.18% H: 0.0% C: 0.0%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| 8.01% | O: -1.1% H: 0.18% C: -1.98%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -14.36% | O: -15.73% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 7.66% | O: -0.42% H: 0.13% C: -1.99%
AMGN | $262.77 -0.49% -0.49% 2M |

Health Technology

| -1.77% | O: -0.28% H: 0.15% C: -2.74%
cancer therapeutics growth market

---

Key Players in Motion Sickness Drugs Market Include GlaxoSmithKline, Novartis, and Teva Pharmaceuticals
Published: 2023-10-27 (Crawled : 01:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K |

Health Technology

| -1.63% | O: -3.68% H: 0.0% C: 0.0%
VTRS | $11.11 0.09% 0.09% 3.5M |

Health Technology

| 23.69% | O: 0.0% H: 0.17% C: -2.45%
PBH | $68.35 0.47% 0.0% 220K |

Health Technology

| 14.03% | O: -0.28% H: 0.57% C: -1.08%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -1.29% | O: -0.23% H: 0.08% C: -1.92%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 10.99% | O: -0.7% H: 0.0% C: -2.46%
BAX | $39.65 0.33% 0.0% 2.3M |

Health Technology

| 22.34% | O: 0.71% H: 0.26% C: -1.59%
ABT | News | $105.27 -0.6% -0.15% 7.3M |

Health Technology

| 14.05% | O: 1.57% H: 0.6% C: -2.01%
pharmaceuticals teva market

---

Biosimilars market size to increase by USD 42.22 billion | Market driven by the notable price advantage of biosimilars compared to biologics - Technavio
Published: 2023-10-25 (Crawled : 03:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K |

Health Technology

| -10.43% | O: 0.4% H: 1.29% C: 1.29%
VTRS | $11.11 0.09% 0.09% 3.5M |

Health Technology

| 22.06% | O: -0.44% H: 0.33% C: -1.1%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -1.93% | O: 0.64% H: 0.46% C: -0.09%
ABBV | News | $164.66 0.25% -0.15% 4.5M |

Health Technology

| 13.78% | O: 0.65% H: 0.54% C: -0.58%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -13.13% | O: 1.43% H: 0.64% C: -0.09%
BIIB | $190.55 -0.84% -0.84% 1.5M |

Health Technology

| -22.59% | O: -0.88% H: 0.34% C: -1.27%
AMGN | $262.77 -0.49% -0.49% 2M |

Health Technology

| -4.05% | O: -0.37% H: 0.58% C: -1.07%
advantage market

---

Global Generic Drugs Business Analysis Report 2023-2030: Small-molecule Generic Drugs Account for a Lion's Share, Biosimilars Exhibit Fastest Growth
Published: 2023-10-23 (Crawled : 19:00) - prnewswire.com
ENDPQ | $0.0006 -50.0% 620K |

n/a

| -55.56% | O: -44.44% H: 60.0% C: -20.0%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| 9.34% | O: 1.37% H: 1.36% C: 1.36%
VTRS | $11.11 0.09% 0.09% 3.5M |

Health Technology

| 24.66% | O: 0.45% H: 2.46% C: 1.67%
NVO | $122.75 -1.43% 0.0% 2.8M |

Health Technology

| 28.22% | O: -0.79% H: 1.41% C: 1.21%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 28.15% | O: -0.84% H: 0.0% C: 0.0%
BAX | $39.65 0.33% 0.0% 2.3M |

Health Technology

| 20.85% | O: 0.2% H: 0.9% C: -1.05%
ABT | News | $105.27 -0.6% -0.15% 7.3M |

Health Technology

| 9.5% | O: -1.82% H: 0.0% C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -12.46% | O: 0.77% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 8.27% | O: 0.38% H: 2.31% C: 2.02%
report business global growth

---

Global Acute Myeloid Leukemia (AML) Treatment Market Trends Analysis Report 2023-2028 - Personalized Medicine and Patient Advocacy Drive Opportunities
Published: 2023-10-20 (Crawled : 10:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K |

Health Technology

| -26.37% | O: -4.45% H: 0.0% C: 0.0%
SNYNF | News | $92.7 -2.18% 1.4K |

Health Technology

| -14.38% | O: -3.95% H: 0.0% C: -0.72%
ALPMY | $9.46 -1.11% 500K |

Manufacturing

| -25.1% | O: -2.89% H: 3.67% C: 2.85%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 11.9% | O: 0.42% H: 0.54% C: 0.11%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -13.22% | O: -0.17% H: 0.0% C: 0.0%
AMGN | $262.77 -0.49% -0.49% 2M |

Health Technology

| -5.58% | O: 0.0% H: 0.16% C: -0.64%
report treatment global trends leukemia market

---

Doxorubicin Market size to grow by USD 469.97 million from 2022 to 2027, North America to account for 47% of market growth- Technavio
Published: 2023-10-19 (Crawled : 03:00) - prnewswire.com
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -3.14% | O: -0.19% H: 0.0% C: -1.33%
BAX | $39.65 0.33% 0.0% 2.3M |

Health Technology

| 23.83% | O: -0.09% H: 3.78% C: 1.81%
america doxorubicin market

---

Global Non-Steroidal Anti-inflammatory Drugs Market Analysis Report 2023-2032: North America Dominates the NSAIDs Market, While Asia-Pacific Shows Fastest Growth
Published: 2023-10-18 (Crawled : 15:30) - prnewswire.com
RBGPF | $52.0 6.46% 34K |

Consumer Non-Durables

| -27.31% | O: 2.75% H: 0.0% C: -2.88%
RBGLY | $10.29 -2.05% 1.4M |

Manufacturing

| -27.84% | O: 0.84% H: 1.04% C: 0.07%
VTRS | $11.11 0.09% 0.09% 3.5M |

Health Technology

| 17.92% | O: -1.06% H: 1.39% C: 0.43%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -3.53% | O: 0.21% H: 0.64% C: -0.61%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -7.51% | O: -0.83% H: 0.35% C: -1.72%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -16.36% | O: -1.23% H: 0.0% C: 0.0%
america report global growth market

---

Nootropic Supplement Market to Register US$ 4,180 Million by 2033 Amid Rising Consumer Demand for Organic Health Boosters | Future Market Insights, Inc.
Published: 2023-10-18 (Crawled : 14:00) - prnewswire.com
TEVJF | $12.37 -24.22% 380 |

Health Technology

| Email alert Add to watchlist
organic health market

---

Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
Published: 2023-10-17 (Crawled : 08:00) - biospace.com/
TEVA | $12.78 -3.03% -0.24% 9M |

Health Technology

| 50.8% | O: -0.69% H: 1.27% C: -0.23%
ajovy depression teva migraine study

---

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M |

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M |

Commercial Services

INVO | $1.555 104.6% 51.13% 5M |

Health Technology

ISPC | $0.437 105.16% 49.53% 37M |

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M |

OST | $0.499 21.38% 45.26% 1.9M |

XPON | News | $3.1 60.62% 37.74% 17M |

TIRX | $0.7 44.39% 30.74% 58M |

BNTC | News | $6.92 44.17% 30.64% 3.5M |

Health Technology

GGE | $0.035 19.86% 29.3% 64M |

---

Your saved searches

---